Hypercoagulability markers in patients with peripheral arterial disease: Association to ankle-brachial index

Angiology

Volumn 60, Issue 5, 2009, Pages 529-535

  Mota, Ana Paula Lucas ^a   De Castro Santos, Maria Elizabeth Rennó ^b   Lima E Silva, Francisco Das Chagas ^b   De Carvalho Schachnik, Natália Castro ^a   De Oliveira Sousa, Marinez ^a   Das Graças Carvalho, Maria ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

Ankle brachial index; Hemostasis; Hypercoagulability; Peripheral arterial disease

Indexed keywords

BIOLOGICAL MARKER; D DIMER; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBOMODULIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOFIBRINOLYSIS; MALE;

AGED; ANKLE; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PRESSURE; BRACHIAL ARTERY; BRAZIL; CASE-CONTROL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; SEVERITY OF ILLNESS INDEX; THROMBOMODULIN; THROMBOPHILIA; ULTRASONOGRAPHY, DOPPLER; UP-REGULATION;

EID: 70350516783     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708325444     Document Type: Article

References (29)

1. Ledermann HP, Schulte AC, Heidecker HG, et al. Blood oxygenation level-dependent magnetic resonance imaging of the skeletal muscle in patients with peripheral arterial occlusive disease. Circulation. 2006 ; 113: 2929-2935.
2. Berliner JA, Navab M., Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation. 1995 ; 91: 2488-2496.
3. Criqui MH, Fronek A., Klauber MR, Barret-Connor E., Gabriel S. The sensitivity, specificity and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation. 1985 ; 71: 516-522.
4. Schmieder FA, Camerota AJ ClaudicaÇÄie;o Intermitente: Magnitude do problema, avaliaçäie;o do paciente e estratégias terapêuticas. Am J Cardiol. 2001 ; 87: 3-14.
5. Henker PK, Schmaier A., Wakefield TW Vascular thrombosis due to hypercoagulable states. In: Rutherford RB, ed. Vascular Surgery. Philadelphia, PA: W. B. Saunders; 2005: 568-578.
6. De Fronzo RA Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997 ; 50: 191-197.
7. McDermott MM, Greenland P., Green D., et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation. 2003 ; 107: 3191-3198.
8. Ünlu Y., Karapolat S., Karaca Y., KiziltunÇ A. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. Thromb Res. 2006 ; 117: 357-364.
9. Matsuo T., Kobayashi H., Kario K., Suzuki S. Fibrin D-dimer in thrombogenic disorders. Semin Thromb Haemost. 2000 ; 26: 101-107.
10. McDermott M., Green D., Greenland P., et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003 ; 92: 194-199.
11. Kienast J., Thompson SG, Raskino C., et al. Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemostas. 1993 ; 70: 550-553.
12. Van Der Bom JG, Bots ML, Haverkate F., et al. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb Haemostas. 2001 ; 85: 234-239.
13. Aznar J., Estelles A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis. 1994 ; 24: 243-251.
14. Thogersen AM, Jansson JH, Boman K., Nilsson TK, Weinehall L., Huhtasaari F. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998 ; 98: 2241-2247.
15. Naya M., Tsukamoto T., Inubushi M., et al. Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circulation J. 2007 ; 71: 348-353.
16. Poredos P., Stegnar M., Gacnik A. Alteration of the fibrinolytic system in patients with peripheral arterial occlusive disease. Vasa. 1999 ; 28: 106-111.
17. Esmon CT The endothelial cell protein C receptor. Thromb Haemostas. 2000 ; 83: 639-643.
18. Horne MK 3rd, Merryman PK, Mayo DJ, Gralnick HR, Chang RC, Alexander HR Reductions in tissue plasminogen activator and thrombomodulin in blood draining veins damaged by venous access devices. Thromb Res. 1995 ; 79: 369-376.
19. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT Down regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol. 2001 ; 159: 797-802.
20. Moore KL, Esmon CT, Esmon NL Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989 ; 73: 159-165.
21. Gosk-Bierska I., Wysokin SW, Karnicki K., Adamiec R. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study. Int Angiol. 2008 ; 27: 296-301.
22. Boneu B., Leger P., Arnaud C. Hemostatic system activation and prediction of vascular events in patients presenting with stable peripheral arterial disease of moderate severity. Blood Coagul Fibrinolysis. 1998 ; 9: 129-135.
23. Ibanez B., Vilahur G., Badimon JJ Plaque progression and regression in atherosthrombosis. J Thromb Haemostas. 2007 ; 5 (suppl 1). 292-299.
24. Lassila R., Peltonen S., LepCurrency signntalo M., Saarinen O., Kauhanen P., Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Artherioscler Thromb. 1993 ; 13: 1738-1742.
25. Cushman M., Folsom AR, Wang L., et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003 ; 101: 1243-1248.
26. AnglÉs-Cano E., de la Pea Däaz A., Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann NY Acad Sci. 2001 ; 936: 261-275.
27. Marcovina SM, Koschinsky ML Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003 ; 14: 361-366.
28. Trifiletti A., Bartolone S., Scamardi R., et al. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy. Minerva Cardioangiol. 1999 ; 47: 55-58.
29. Peter K., Nawroth P., Conradt C., et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin and thrombomodulin. Arterioscler Thromb Vasc Biol. 1997 ; 17: 505-512.